Revenue (Disaggregation of Revenue by Product) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 7,810.0	$ 6,805.6
U.S.
Disaggregation of Revenue [Line Items]
Revenue	5,174.6	3,941.3
Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	2,635.4	2,864.3
Diabetes
Disaggregation of Revenue [Line Items]
Revenue	3,388.2	3,111.1
Diabetes | U.S.
Disaggregation of Revenue [Line Items]
Revenue	2,276.6	2,061.2
Diabetes | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,111.6	1,049.9
Trulicity®
Disaggregation of Revenue [Line Items]
Revenue	1,741.3	1,452.4
Trulicity® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,313.9	1,116.8
Trulicity® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	427.4	335.7
Humalog®
Disaggregation of Revenue [Line Items]
Revenue	618.2	617.0
Humalog® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	368.9	332.7
Humalog® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	249.3	284.4
Jardiance
Disaggregation of Revenue [Line Items]
Revenue	419.4	312.0
Jardiance | U.S.
Disaggregation of Revenue [Line Items]
Revenue	229.8	151.2
Jardiance | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	189.7	160.8
Humulin®
Disaggregation of Revenue [Line Items]
Revenue	273.2	321.7
Humulin® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	190.4	219.0
Humulin® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	82.8	102.7
Basaglar®
Disaggregation of Revenue [Line Items]
Revenue	191.5	246.6
Basaglar® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	119.3	175.2
Basaglar® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	72.2	71.4
Other diabetes
Disaggregation of Revenue [Line Items]
Revenue	144.6	161.4
Other diabetes | U.S.
Disaggregation of Revenue [Line Items]
Revenue	54.3	66.3
Other diabetes | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	90.2	94.9
Oncology
Disaggregation of Revenue [Line Items]
Revenue	1,353.0	1,372.2
Oncology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	783.7	642.5
Oncology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	569.2	729.7
Verzenio®
Disaggregation of Revenue [Line Items]
Revenue	469.4	269.0
Verzenio® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	301.5	172.8
Verzenio® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	167.9	96.2
Alimta®
Disaggregation of Revenue [Line Items]
Revenue	343.9	559.0
Alimta® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	254.3	261.1
Alimta® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	89.7	297.8
Cyramza®
Disaggregation of Revenue [Line Items]
Revenue	230.3	240.5
Cyramza® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	79.2	80.2
Cyramza® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	151.1	160.3
Erbitux®
Disaggregation of Revenue [Line Items]
Revenue	122.7	122.4
Erbitux® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	109.7	107.9
Erbitux® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	13.0	14.4
Tyvyt®
Disaggregation of Revenue [Line Items]
Revenue	85.5	109.7
Tyvyt® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	0.0	0.0
Tyvyt® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	85.5	109.7
Other oncology
Disaggregation of Revenue [Line Items]
Revenue	101.2	71.6
Other oncology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	39.0	20.5
Other oncology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	62.0	51.3
Immunology
Disaggregation of Revenue [Line Items]
Revenue	748.1	613.9
Immunology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	378.5	284.8
Immunology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	369.6	329.1
Taltz®
Disaggregation of Revenue [Line Items]
Revenue	488.1	403.2
Taltz® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	307.2	249.6
Taltz® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	180.8	153.6
Olumiant®
Disaggregation of Revenue [Line Items]
Revenue	255.6	193.8
Olumiant® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	71.3	24.7
Olumiant® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	184.3	169.1
Other immunology
Disaggregation of Revenue [Line Items]
Revenue	4.5	16.9
Other immunology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	0.0	10.5
Other immunology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	4.5	6.4
Neuroscience
Disaggregation of Revenue [Line Items]
Revenue	397.7	465.4
Neuroscience | U.S.
Disaggregation of Revenue [Line Items]
Revenue	153.4	141.7
Neuroscience | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	244.4	323.7
Emgality®
Disaggregation of Revenue [Line Items]
Revenue	149.3	119.5
Emgality® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	108.3	101.5
Emgality® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	41.0	18.0
Zyprexa®
Disaggregation of Revenue [Line Items]
Revenue	93.1	95.8
Zyprexa® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	9.6	6.9
Zyprexa® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	83.5	88.9
Cymbalta®
Disaggregation of Revenue [Line Items]
Revenue	81.1	176.6
Cymbalta® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	9.1	11.0
Cymbalta® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	71.9	165.7
Other neuroscience
Disaggregation of Revenue [Line Items]
Revenue	74.2	73.5
Other neuroscience | U.S.
Disaggregation of Revenue [Line Items]
Revenue	26.4	22.3
Other neuroscience | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	48.0	51.1
Other
Disaggregation of Revenue [Line Items]
Revenue	1,923.0	1,242.9
Other | U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,582.4	811.1
Other | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	340.6	431.8
COVID-19 Antibodies
Disaggregation of Revenue [Line Items]
Revenue	1,469.8	810.1
COVID-19 Antibodies | U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,455.2	650.6
COVID-19 Antibodies | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	14.7	159.5
Cialis®
Disaggregation of Revenue [Line Items]
Revenue	217.7	126.8
Cialis® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	6.9	8.6
Cialis® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	210.8	118.1
Forteo®
Disaggregation of Revenue [Line Items]
Revenue	137.4	198.5
Forteo® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	70.2	97.7
Forteo® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	67.3	100.8
Other
Disaggregation of Revenue [Line Items]
Revenue	98.1	107.5
Other | U.S.
Disaggregation of Revenue [Line Items]
Revenue	50.1	54.2
Other | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	$ 47.8	$ 53.4